Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vaccine makers could make Omicron-specific booster, says Fauci

12/03/2021 | 12:15pm EST

WASHINGTON, Dec 3 (Reuters) - COVID-19 vaccine makers have contingency plans to deal with the Omicron variant that include a combination vaccine against the original version and the variant as well as a variant-specific booster dose, a top U.S. health official said on Friday.

The U.S. government is working with Moderna, Pfizer, and J&J on multiple contingency plans, infectious disease expert Anthony Fauci told reporters at a White House briefing.

"One is to rev up the production of the vaccines that they already have. The next is to make, for example, a bivalent, where you have the vaccine against both the ancestral strain and the new variant, and the other is to make a variant-specific boost," said Fauci.

"They are now assuming they may have to do that and are being prepared for that," he added.

Data from a National Institutes of Health study strongly suggest that existing boosters provide cross protection against a number of variants, including Omicron, Fauci said.

"Although we haven't proven it yet, there's every reason to believe that if you get vaccinated and boosted that you would have at least some degree of cross protection, very likely against severe disease, even against the Omicron variant."

The U.S. Centers for Disease Control and Prevention is working with local authorities to investigate suspect cases of the Omicron variant in states other than those where cases have already been reported, Director Rochelle Walensky said at the briefing.

There have been cases of Omicron detected in about 40 countries, she said, but the Delta variant remains the dominant strain in the United States.

"I know that the news is focused on Omicron. But we should remember that 99.9% of cases in the country right now are from the Delta variant. Delta continues to drive cases across the country, especially in those who are unvaccinated," she said. (Reporting by Ahmed Aboulenein and Jeff Mason; Additional reporting by Doina Chiacu; Editing by Rosalba O'Brien and Dan Grebler)


ę Reuters 2021
All news about MODERNA, INC.
01/27Pfizer/BioNTech, Moderna COVID-19 Booster Shots Provide Protection Against Death from O..
MT
01/27Moderna, IAVI Say Clinical Trial of Experimental HIV Vaccine Antigens is Underway
MT
01/27MODERNA : IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Tec..
PU
01/27WALL STREET STOCK EXCHANGE : Are we still in the Goldilocks zone?
01/27MARKETSCREENER'S WORLD PRESS REVIEW : January 27, 2022
01/26Pfizer-BioNTech, Moderna COVID-19 Jabs Shown Safe For Women Undergoing IVF in Study
MT
01/26Moderna Launches Mid-Stage Study of Omicron-Specific Booster Jab
MT
01/26Moderna starts trial for Omicron-specific booster shot
RE
01/26Moderna starts trial testing Omicron-specific booster shot
RE
01/26MODERNA : Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster C..
PU
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 766 M - -
Net income 2021 11 257 M - -
Net cash 2021 11 938 M - -
P/E ratio 2021 5,59x
Yield 2021 -
Capitalization 60 258 M 60 258 M -
EV / Sales 2021 2,72x
EV / Sales 2022 1,72x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 148,62 $
Average target price 262,47 $
Spread / Average Target 76,6%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-41.48%60 258
LONZA GROUP AG-19.46%48 939
IQVIA HOLDINGS INC.-17.77%44 321
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892
CELLTRION, INC.-25.51%17 086